Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections

被引:123
|
作者
Thangamani, Shankar [1 ]
Younis, Waleed [1 ]
Seleem, Mohamed N. [1 ]
机构
[1] Purdue Univ, Coll Vet Med, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA
来源
SCIENTIFIC REPORTS | 2015年 / 5卷
关键词
CA-MRSA SKIN; IN-VITRO; AUREUS; ANTIBIOTICS; INFLAMMATION; ANTIOXIDANT; EXPRESSION; SUSCEPTIBILITY; CHOLESTEROL; INHIBITION;
D O I
10.1038/srep11596
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Novel antimicrobials and new approaches to developing them are urgently needed. Repurposing already-approved drugs with well-characterized toxicology and pharmacology is a novel way to reduce the time, cost, and risk associated with antibiotic innovation. Ebselen, an organoselenium compound, is known to be clinically safe and has a well-known pharmacology profile. It has shown potent bactericidal activity against multidrug-resistant clinical isolates of staphylococcus aureus, including methicillin- and vancomycin-resistant S. aureus (MRSA and VRSA). We demonstrated that ebselen acts through inhibition of protein synthesis and subsequently inhibited toxin production in MRSA. Additionally, ebselen was remarkably active and significantly reduced established staphylococcal biofilms. The therapeutic efficacy of ebselen was evaluated in a mouse model of staphylococcal skin infections. Ebselen 1% and 2% significantly reduced the bacterial load and the levels of the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-1 beta (IL-1 beta), and monocyte chemo attractant protein-1 (MCP-1) in MRSA USA300 skin lesions. Furthermore, it acts synergistically with traditional antimicrobials. This study provides evidence that ebselen has great potential for topical treatment of MRSA skin infections and lays the foundation for further analysis and development of ebselen as a potential treatment for multidrug-resistant staphylococcal infections.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Novel therapies for treatment of multidrug-resistant Acinetobacter baumannii skin infections
    Mihu, Mircea Radu
    Martinez, Luis R.
    VIRULENCE, 2011, 2 (02) : 97 - 102
  • [42] Durlobactam in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections: A Systematic Review
    Granata, Guido
    Taglietti, Fabrizio
    Schiavone, Francesco
    Petrosillo, Nicola
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (12)
  • [43] Ceftolozane/Tazobactam Treatment of Multidrug-resistant Pseudomonas aeruginosa Infections in Children
    Molloy, Leah
    Abdulhamid, Ibrahim
    Srivastava, Ruma
    Ang, Jocelyn Y.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2020, 39 (05) : 419 - 420
  • [44] Multidrug-Resistant Gram-Negative Infections What are the Treatment Options?
    Giamarellou, Helen
    Poulakou, Garyphallia
    DRUGS, 2009, 69 (14) : 1879 - 1901
  • [45] A Review of Ceftolozane/Tazobactam for the Treatment of Infections Caused by Multidrug-Resistant Pathogens
    Sebaaly, Jamielynn
    Woods, Joseph Andrew
    Wargo, Kurt A.
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 2018, 26 (04) : 198 - 203
  • [46] Effectiveness and Safety of Colistin for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections
    Montero, M.
    Horcajada, J. P.
    Sorli, L.
    Alvarez-Lerma, F.
    Grau, S.
    Riu, M.
    Sala, M.
    Knobel, H.
    INFECTION, 2009, 37 (05) : 461 - 465
  • [47] Novel approaches for the treatment of infections due to multidrug-resistant bacterial pathogens
    Imran, Mohmmad
    Ahmad, Mohammad Naiyaz
    Dasgupta, Arunava
    Rana, Preeti
    Srinivas, Nanduri
    Chopra, Sidharth
    FUTURE MEDICINAL CHEMISTRY, 2022, 14 (15) : 1133 - 1148
  • [48] Potential of doripenem for the treatment of infections with multidrug-resistant Pseudomonas spp.
    Naesens, R.
    Jansens, H.
    Goossens, H.
    Ieven, M.
    Vlieghe, E.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2010, 35 (05) : 514 - 515
  • [49] Improved treatment of multidrug-resistant bacterial infections: utility of clinical studies
    Bettiol, Esther
    Rottier, Wouter C.
    Dolores del Toro, Maria
    Harbarth, Stephan
    Bonten, Marc J.
    Rodriguez-Bano, Jesus
    FUTURE MICROBIOLOGY, 2014, 9 (06) : 757 - 771
  • [50] Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections
    M. Montero
    J. P. Horcajada
    L. Sorlí
    F. Alvarez-Lerma
    S. Grau
    M. Riu
    M. Sala
    H. Knobel
    Infection, 2009, 37 : 461 - 465